Drug Trial Radar · NCT03048825
Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry
Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,264
Actual
Start
Feb 1, 2018
Primary completion
Aug 9, 2024
Study completion Aug 9, 2024
Sponsor
- Lead sponsor
- Population Health Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Boston Scientific Corporation; Canadian Institutes of Health Research (CIHR)
- First posted
- Feb 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The CLEAR SYNERGY trial will study the long term effects of treatments following PCI to treat myocardial infarction. These treatments address both the culprit artery (PCI with SYNERGY stent) as well as the non-culprit arteries (randomization to routine colchicine and spironolactone).
Conditions
- ST Elevation Myocardial Infarction
- Non ST Elevation Myocardial Infarction
Interventions
ColchicineDrug
Colchicine 0.5 mg once daily
SpironolactoneDrug
Spironolactone 25 mg once daily
SYNERGY Bioabsorbable Polymer Drug-Eluting StentDevice
Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.
Colchicine-PlaceboDrug
Matching Colchicine-placebo once daily
Spironolactone-PlaceboDrug
Matching Spironolactone-Placebo once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Adverse Cardiac Events (MACE)Time frame: up to 1 year
- Composite of cardiovascular death, recurrent myocardial infarction, stroke, or unplanned ischemia driven revascularizationTime frame: through study completion, an estimated average of 3 years
- Total composite events of cardiovascular death or new or worsening heart failure (co-primary 1)Time frame: through study completion, an estimated average of 3 years
- Composite of cardiovascular death, new or worsening heart failure, recurrent myocardial infarction, or stroke (co-primary 2)Time frame: through study completion, an estimated average of 3 years
Locations
109 sites in 14 countries. Site status is shown where the registry gives one.
Central Cardiology
Bakersfield, California
Medstar Washington Hospital Center
Washington D.C., District of Columbia
University of Illinois
Chicago, Illinois
Prairie Education & Research Cooperative
Springfield, Illinois
Community Hospital
Munster, Indiana
Lahey Hospital and Medical Center
Burlington, Massachusetts
New Mexico Heart Institute
Albuquerque, New Mexico
NYU Langone Medical Center
New York, New York
The Christ Hospital Lindner Research Center
Cincinnati, Ohio
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Bankstown-Lidcombe hospital
Bankstown, New South Wales, Australia
SWSLHD - Campbelltown
Campbelltown, New South Wales, Australia
SWSLHD - Liverpool Hospital
Liverpool, New South Wales, Australia
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Peninsula Health
Frankston, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
University of Alberta Hospital
Edmonton, Alberta, Canada
Kelowna General Hospital
Kelowna, British Columbia, Canada
Fraser Clinical Trials
New Westminster, British Columbia, Canada
Victoria Heart Institute Foundation
Victoria, British Columbia, Canada
William Osler Health
Brampton, Ontario, Canada
Hamilton General Hospital
Hamilton, Ontario, Canada
Kingston Health Science Centre
Kingston, Ontario, Canada
St. Mary's General Hospital
Kitchener, Ontario, Canada
London Health Sciences Centre
London, Ontario, Canada
York PCI Group Inc
Newmarket, Ontario, Canada
University of Ottawa Heart Institute
Ottawa, Ontario, Canada
Niagara Health System
Saint Catharines, Ontario, Canada
Scarborough Cardiology Research Associates Inc.
Scarborough Village, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Toronto General Hospital, University Health Network
Toronto, Ontario, Canada
Windsor Regional Hospital
Windsor, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Institut Universitaire de Cardiologie et de Pneumologie - ULAVAL
Québec, Quebec, Canada
CIUSSS de l'Estrie - CHUS - Hôpital Fleurimont
Sherbrooke, Quebec, Canada
PVRI - Regina General Hospital
Regina, Saskatchewan, Canada
Royal University Hospital
Saskatoon, Saskatchewan, Canada
Czech Center University Hospital Brno
Brno, Czechia
Showing 40 of 109 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.